- Home
- PSNL vs ARVN Comparison
PSNL vs ARVN Comparison
Compare PSNL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | ARVN |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 781.0M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PSNL | ARVN |
|---|---|---|
| Price | $7.77 | $10.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 20 |
| Target Price | $12.20 | ★ $15.35 |
| AVG Volume (30 Days) | ★ 1.4M | 736.2K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.58 | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | $69,648,000.00 | ★ $262,600,000.00 |
| Revenue This Year | $15.47 | N/A |
| Revenue Next Year | $39.24 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $5.90 |
| 52 Week High | $11.50 | $14.22 |
Technical Indicators
Market Signals| Indicator | PSNL | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 36.41 |
| Support Level | $7.74 | $9.02 |
| Resistance Level | $7.78 | $14.03 |
| Average True Range (ATR) | 0.53 | 0.67 |
| MACD | 0.06 | -0.28 |
| Stochastic Oscillator | 63.83 | 20.47 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.